Our Investors
Backed by a premier group of life sciences investors committed to advancing breakthrough therapies for protein misfolding diseases.
Accelerating the development of first-in-class small molecule treatments that restore protein function and address critical unmet medical needs.
Transforming the lives of patients suffering from protein misfolding diseases through innovative pharmacological chaperones.
Learn More →Our integrated approach combines protein sciences, advanced computation, and medicinal chemistry.
Learn More →Targeting serious conditions stemming from protein misfolding, from cardiomyopathy to AL amyloidosis.
Learn More →Advancing multiple programs from target identification through clinical validation.
Learn More →Building upon the breakthrough success of tafamidis, discovered by our cofounders.
Learn More →Decades of experience in drug discovery, clinical development, and biotechnology innovation.
Meet the Team →We're building a team of passionate scientists and professionals dedicated to bringing life-changing therapies to patients in need.
Backed by a premier group of life sciences investors committed to advancing breakthrough therapies for protein misfolding diseases.